Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

vTv Therapeutics (VTVT) Net Income towards Common Stockholders: 2013-2024

Historic Net Income towards Common Stockholders for vTv Therapeutics (VTVT) over the last 12 years, with Dec 2024 value amounting to -$18.5 million.

  • vTv Therapeutics' Net Income towards Common Stockholders fell 81.85% to -$8.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$23.5 million, marking a year-over-year decrease of 28.21%. This contributed to the annual value of -$18.5 million for FY2024, which is 8.83% up from last year.
  • As of FY2024, vTv Therapeutics' Net Income towards Common Stockholders stood at -$18.5 million, which was up 8.83% from -$20.2 million recorded in FY2023.
  • In the past 5 years, vTv Therapeutics' Net Income towards Common Stockholders ranged from a high of -$8.5 million in FY2020 and a low of -$20.2 million during FY2023.
  • Over the past 3 years, vTv Therapeutics' median Net Income towards Common Stockholders value was -$19.2 million (recorded in 2022), while the average stood at -$19.3 million.
  • Per our database at Business Quant, vTv Therapeutics' Net Income towards Common Stockholders surged by 52.55% in 2020 and then slumped by 52.81% in 2021.
  • Yearly analysis of 5 years shows vTv Therapeutics' Net Income towards Common Stockholders stood at -$8.5 million in 2020, then tumbled by 52.81% to -$13.0 million in 2021, then plummeted by 47.56% to -$19.2 million in 2022, then fell by 5.67% to -$20.2 million in 2023, then rose by 8.83% to -$18.5 million in 2024.